FELDING, JAKOB,LIANG, XIFU,HORNEMAN, ANNE MARIE,POULSEN, TINA, DAHLERUP,LARSEN, JENS, CHRISTIAN, HOJLAND
申请号：
NZ59182009
公开号：
NZ591820A
申请日:
2009.08.27
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
591820 Disclosed are amides and thioamides of formula I. Specific examples of compounds of formula I include: (4-{ [2-(3,3-Dimethyl-butylcarbamoyl)-phenylamino]-methyl} -pyridin-2-yl)carbamic acid methyl ester, 2-[(2-Acetylamino-pyridin-4-ylmethyl)-amino]-N-(3-ethyI-pentyl)-benzamide, Furan-2-carboxylic acid (4-{ [2-(4-methyl-pentylcarbamoyl)-phenylamino]-methyl} -pyridin-2-yl)-amide, and Furan-2-carboxylic acid (4-{ [2-(3-ethyl-pentylcarbamoyl)-phenylamino]-methyl} -pyridin-2-yl)-amide. Compounds of formula I exhibit a high receptor tyrosine kinase inhibitory activity on the receptor VEGFR-2, also referred to as the KDR receptor. The compounds inhibit angiogenesis, which is beneficial for treating diseases such as atherosclerosis, inflammatory conditions such as dermatitis, psoriasis, rosacea and rheumatoid arthritis, eye diseases such as diabetic retinopathy and macular degeneration, and cancer.
